Merck Comprehensive Income 2010-2024 | MRK
Merck comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Merck comprehensive income for the quarter ending September 30, 2024 was $-5.371B, a 9.26% increase year-over-year.
- Merck comprehensive income for 2023 was $-5.161B, a 8.24% increase from 2022.
- Merck comprehensive income for 2022 was $-4.768B, a 7.65% increase from 2021.
- Merck comprehensive income for 2021 was $-4.429B, a 33.24% decline from 2020.
Merck Annual Comprehensive Income
(Millions of US $) |
| 2023 |
$-5,161 |
| 2022 |
$-4,768 |
| 2021 |
$-4,429 |
| 2020 |
$-6,634 |
| 2019 |
$-6,193 |
| 2018 |
$-5,545 |
| 2017 |
$-4,910 |
| 2016 |
$-5,226 |
| 2015 |
$-4,148 |
| 2014 |
$-4,323 |
| 2013 |
$-2,197 |
| 2012 |
$-4,682 |
| 2011 |
$-3,132 |
| 2010 |
$-3,216 |
| 2009 |
$-2,767 |
Merck Quarterly Comprehensive Income
(Millions of US $) |
| 2024-09-30 |
$-5,371 |
| 2024-06-30 |
$-5,361 |
| 2024-03-31 |
$-5,274 |
| 2023-12-31 |
$-5,161 |
| 2023-09-30 |
$-4,916 |
| 2023-06-30 |
$-4,900 |
| 2023-03-31 |
$-4,883 |
| 2022-12-31 |
$-4,768 |
| 2022-09-30 |
$-4,743 |
| 2022-06-30 |
$-4,327 |
| 2022-03-31 |
$-4,369 |
| 2021-12-31 |
$-4,429 |
| 2021-09-30 |
$-4,590 |
| 2021-06-30 |
$-4,628 |
| 2021-03-31 |
$-6,622 |
| 2020-12-31 |
$-6,634 |
| 2020-09-30 |
$-6,383 |
| 2020-06-30 |
$-6,393 |
| 2020-03-31 |
$-6,391 |
| 2019-12-31 |
$-6,193 |
| 2019-09-30 |
$-5,390 |
| 2019-06-30 |
$-5,362 |
| 2019-03-31 |
$-5,346 |
| 2018-12-31 |
$-5,545 |
| 2018-09-30 |
$-5,151 |
| 2018-06-30 |
$-5,122 |
| 2018-03-31 |
$-5,060 |
| 2017-12-31 |
$-4,910 |
| 2017-09-30 |
$-4,945 |
| 2017-06-30 |
$-5,094 |
| 2017-03-31 |
$-5,080 |
| 2016-12-31 |
$-5,226 |
| 2016-09-30 |
$-4,252 |
| 2016-06-30 |
$-4,086 |
| 2016-03-31 |
$-4,194 |
| 2015-12-31 |
$-4,148 |
| 2015-09-30 |
$-4,573 |
| 2015-06-30 |
$-4,332 |
| 2015-03-31 |
$-4,167 |
| 2014-12-31 |
$-4,323 |
| 2014-09-30 |
$-2,998 |
| 2014-06-30 |
$-2,444 |
| 2014-03-31 |
$-2,179 |
| 2013-12-31 |
$-2,197 |
| 2013-09-30 |
$-4,698 |
| 2013-06-30 |
$-4,760 |
| 2013-03-31 |
$-4,629 |
| 2012-12-31 |
$-4,682 |
| 2012-09-30 |
$-3,040 |
| 2012-06-30 |
$-3,126 |
| 2012-03-31 |
$-3,217 |
| 2011-12-31 |
$-3,132 |
| 2011-09-30 |
$-2,713 |
| 2011-06-30 |
$-2,776 |
| 2011-03-31 |
$-3,170 |
| 2010-12-31 |
$-3,216 |
| 2010-09-30 |
$-3,490 |
| 2010-06-30 |
$-4,659 |
| 2010-03-31 |
$-3,572 |
| 2009-12-31 |
$-2,767 |
| 2009-09-30 |
$-2,675 |
| 2009-06-30 |
$-2,550 |
| 2009-03-31 |
$-2,473 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$260.350B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
